Methodology

All entries for: MyoPax GmbH

November 6, 2025

MyoPax GmbH

Orphan Drug Designation

FDA orphan drug designation: treatment of limb girdle muscular dystrophy 2A

Disease Area: Rare Diseases
Source
Scroll to Top